Cancer screenings that utilize blood tests such as for prostate cancer (testing for prostate-specific antigen) have tended to have a lower deficit compared to cancer screenings that involve procedures such as colonoscopy and mammography (4). This evidence concerns the gene KLK3 and prostate cancer.